Regulatory Affairs Management
Leading regulatory affairs managers can act as a seamless extension of Sponsor regulatory teams.
Thanks to MMS and especially the team… we reset the relationship that we have with the FDA and moved our lead asset forward through to getting our clinical trial started.
MMS regulatory strategy experts provide consulting and can be assigned as the product lead or a lead for a specific submission type, if needed.
MMS Regulatory Affairs Managers are a true extension of Sponsor regulatory affairs teams. These knowledgeable, experienced resources are assigned to specific products and applications and work with Sponsor teams to execute regulatory activities and facilitate optimal progress and development.
Our Regulatory Affairs Managers are responsible to support the following:
- Communication of regulatory requirements and provision of status updates to stakeholders in the Sponsor company
- Development of Module 1 content required for global health authority interactions, including the FDA, EMA, and others
- Review of required regulatory documentation and files created by other functional lines
- Representation to and interactions with global health authorities on behalf of the Sponsor
Leads the team in the preparation and execution of large and/or complex dossiers
For more information on submissions support, see here.
Regulatory Affairs Managers and Strategists regularly create regional, Module 1 documentation and provide the Sponsor team with expert guidance on the content and format needed to support key interactions with global health authorities.
Suggested For You
webinar
September 26th, 2024
Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance
regulatory intelligence
August 27th, 2024
Recent Guidance on Diversity Action Planning
regulatory intelligence
August 26th, 2024
Oncology Programs at the FDA
regulatory intelligence
August 26th, 2024
Three Key Take Reflections on the Recent Donanemab Approval
webinar
September 12th, 2024
No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology
regulatory intelligence
August 9th, 2024
FDA Updates 2024 Language Access Plan
regulatory intelligence
August 3rd, 2024
EMA Launches New Pilot Program for Orphan Medical Devices
perspectives
July 30th, 2024
The Critical Role of Quality Control (QC) – Medical Writing and Beyond
regulatory intelligence
July 26th, 2024
Key Decision Points for Recent Oncology Approvals
regulatory intelligence
July 24th, 2024
Comments Open for Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products
perspectives
July 23rd, 2024
PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma
news
July 17th, 2024
Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization